PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA Biotech’s technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With steadfast commitment to research and innovation, PanGIA Biotech’s vision is to revolutionize disease detection and improve healthcare worldwide.